Emergence of chemoresistance in a metastatic basal cell carcinoma patient after complete response to hedgehog pathway inhibitor vismodegib (GDC-0449)

Australasian Journal of Dermatology

Volumn 55, Issue 3, 2014, Pages 218-221

  Meani, Rowena E ^a   Lim, Shueh Wen ^a   Chang, Anne Lynn S ^b   Kelly, John W ^a  

^a Victorian Melanoma Service   (Australia)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

advanced BCC; basal cell carcinoma (BCC); chemoresistance; Hedgehog inhibitor; metastatic BCC; secondary resistance; vismodegib

Indexed keywords

ANILIDE; ANTINEOPLASTIC AGENT; PYRIDINE DERIVATIVE; SONIC HEDGEHOG PROTEIN; VISMODEGIB;

AGED; ANTAGONISTS AND INHIBITORS; BONE NEOPLASMS; CARCINOMA, BASAL CELL; CASE REPORT; DRUG EFFECTS; DRUG RESISTANCE; HUMAN; LUNG NEOPLASMS; LYMPH NODE METASTASIS; MALE; PATHOLOGY; RIB; SECONDARY; SIGNAL TRANSDUCTION; SKIN NEOPLASMS;

AGED; ANILIDES; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; CARCINOMA, BASAL CELL; DRUG RESISTANCE, NEOPLASM; HEDGEHOG PROTEINS; HUMANS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; PYRIDINES; RIBS; SIGNAL TRANSDUCTION; SKIN NEOPLASMS;

EID: 84905920758     PISSN: 00048380     EISSN: 14400960     Source Type: Journal    
DOI: 10.1111/ajd.12196     Document Type: Article

References (13)

1. Wadhera A, Fazio M, Bricca G, et al. Metastatic basal cell carcinoma: a case report and literature review. How accurate is our incidence data? Dermatol. Online J. 2006; 12: 7.
2. Von Hoff DD, LoRusso PM, Rudin CM, et al. Inhibition of the Hedgehog pathway in advanced basal-cell carcinoma. N. Engl. J. Med. 2009; 361: 1164-1172.
3. Danial D, Ligala B, Balise R, et al. Markedly improved overall survival in 10 consecutive patients with metastic basal cell carcinoma. Br. J. Dermatol. 2013; 169: 673-676.
4. Epstein EH,. Basal cell carcinomas: attack of the Hedgehog. Nat. Rev. Cancer 2008; 8: 743-754.
5. Scales SJ, de Sauvage FJ,. Mechanisms of Hedgehog pathway activation in cancer and implications for therapy. Trends Pharmacol. Sci. 2009; 30: 303-312.
6. Rubin LL, de Sauvage FJ,. Targeting the Hedgehog pathway in cancer. Nat. Rev. Drug Discov. 2006; 5: 1026-1033.
7. Reifenberger J, Wolter M, Knobbe CB, et al. Somatic mutations in the PTCH, SMOH, SUFUH and TP53 genes in sporadic basal cell carcinomas. Br. J. Dermatol. 2005; 152: 43-51.
8. Sekulic A, Migden MR, Oro AE, et al. Efficacy and safety of vismodegib in advanced basal cell carcinoma. N. Engl. J. Med. 2012; 366: 2171-2179.
9. Chen JK, Taipale J, Cooper MK, et al. Inhibition of Hedgehog signaling by direct binding of cyclopamine to Smoothened. Genes Dev. 2002; 16: 2743-2748.
10. Chang AS, Solomon JA, Hainsworth JD, et al. Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib. J. Am. Acad. Dermatol. 2014; 1: 60-69.
11. LoRusso PM, Rudin CM, Reddy JC, et al. Phase I trial of Hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors. Clin. Cancer Res. 2011; 17: 2502-2511.
12. Rudin CM, Hann CL, Laterra J, et al. Treatment of medulloblastoma with Hedgehog pathway inhibitor GDC-0449. N. Engl. J. Med. 2009; 361: 1173-1178.
13. Chang AS, Oro AE,. Initial assessment of tumor regrowth after vismodegib in advanced basal cell carcinoma. Arch. Dermatol. 2012; 148: 1324-1325.